Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LNPEP | Q9UIQ6 | 5/20 | 0.61 |
| ▸ | BMP1 | P13497 | 1/20 | 0.59 |
| ▸ | TACR1 | P25103 | 4/20 | 0.57 |
| ▸ | ERAP1 | Q9NZ08 | 7/20 | 0.57 |
| ▸ | ERAP2 | Q6P179 | 7/20 | 0.57 |
| ▸ | PPARG | P37231 | 1/20 | 0.57 |
| ▸ | IL1RN | P18510 | 3/20 | 0.56 |
| ▸ | ACE | P12821 | 1/20 | 0.56 |
| ▸ | PLG | P00747 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9966740 | 0.93 | MEN1 (0.65) | LNPEPBMP1TACR1ERAP1ERAP2 | |
| SCHEMBL15591438 | 0.93 | MEN1 (0.65) | LNPEPBMP1TACR1ERAP1ERAP2 | |
| SCHEMBL9931405 | 0.92 | LNPEP (0.67) | LNPEPBMP1TACR1ERAP1ERAP2 | |
| Hydrochloric Acid SCHEMBL645269 | 0.92 | MEN1 (0.64) | LNPEPBMP1TACR1ERAP1ERAP2 | |
| SCHEMBL9970156 | 0.91 | LNPEP (0.60) | LNPEPTACR1ERAP1ERAP2IL1RN | |
| SCHEMBL16254021 | 0.89 | POLB (0.60) | ERAP2PPARGACE | |
| SCHEMBL16250728 | 0.89 | MEN1 (0.65) | ERAP2PPARGACE | |
| SCHEMBL12966277 | 0.89 | ERAP2 (0.60) | LNPEPTACR1ERAP1ERAP2IL1RN | |
| Golotimod SCHEMBL726938 | 0.88 | KDM4E (0.65) | ERAP2PPARGACE | |
| Golotimod SCHEMBL12818886 | 0.88 | KDM4E (0.65) | ERAP2PPARGACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140343050-A1 | PRODRUGS OF D-ISOGLUTAMYL-[D/L]-TRYPTOPHAN | APTOEX TECHNOLOGIES, INC. (CA) | 2014-11-20 | — | — | US | disclosed |
| US-20140343050-A1 | PRODRUGS OF D-ISOGLUTAMYL-[D/L]-TRYPTOPHAN | APTOEX TECHNOLOGIES, INC. (CA) | 2014-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343050-A1 | PRODRUGS OF D-ISOGLUTAMYL-[D/L]-TRYPTOPHAN | TPH1, TYMS, TDO2 | LNPEP 150/4885BMP1 3128/4885TACR1 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.